Thyrocare Technologies Limited reports revenue of INR 223.95 Cr in Q4FY26 with a growth of 20% YoY

•  Thyrocare expanded it’s tests portfolio with advanced allergy testing (250+ SKUs on the Phadia platform) and forayed into genomics with a state-of-the-art lab and launch of NIPT, alongside a phased expansion of it’s test menu to deepen clinical offerings in precision diagnostics

• Consolidated revenue registered a 20% year-on-year growth, driven primarily by a 21% increase in the Pathology segment
• In the Pathology business, franchise revenue grew by 21% year-on-year, while partnership revenue recorded 23% year-on-year growth
• Thyrocare, India’s largest diagnostic test volume processor, processed 59.0 million tests in Q4FY26, marking a strong 29% year-on-year growth and reinforcing its volume leadership position in the industry
• Consolidated EBITDA grew by 31% year-on-year, and Profit After Tax (PAT) grew by 128% year-on-year to Rs 48.70 Cr
• Sustained Six Sigma quality standards, reducing complaints per million tests to 3.1 (down 34% YoY) with ATAT at 3.43 hours - India's first diagnostic chain to hit this benchmark

Key Financial Highlights for FY26

• Consolidated revenue grew by 21% year-on-year to Rs 829.04 Cr
• In the Pathology business, franchise revenue grew by 18% year-on-year, while partnership revenue recorded a robust 32% year-on-year growth
• Test volumes, processed stood at 209.6 million tests in FY26, marking a strong 23% year-on-year growth
• Consolidated EBITDA grew by 38% year-on-year, and Profit After Tax (PAT) grew by 81% year-on-year to Rs 162.85 Cr

Thyrocare Reports Robust Q4FY26 Results – Revenue Up 20%, PAT Up 128%

The company delivered a robust performance in Q4FY26 with consolidated revenue of ₹223.95 crore, registering a strong 20% year-on-year growth, led by continued momentum in the Pathology segment which grew 21% YoY. EBITDA rose by 31% YoY to ₹75.09 crore. Profit After Tax surged 128% YoY to ₹48.70 crore, underscoring the company’s focus on profitable growth.

India’s largest diagnostic test volume processor further strengthened its volume leadership position during the quarter, processing 59.0 million tests up 29% year-on-year. The Pathology business maintained strong traction with franchise revenue up 21% and partnership revenue up 23% (normalised partnership revenue up by 32% after adjusting one off camp revenue in Q4FY-25) year-on-year.

Thyrocare's unwavering commitment to quality delivered Six Sigma excellence by reducing complaints to 3.1 per million (down 34% YoY) with ATAT at 3.43 hours from sample receipt, positioning the company as India's first diagnostic chain to attain this benchmark.

Thyrocare's expanded it’s test portfolio with advanced allergy testing (250+SKUs on the Phadia platform) and entered genomics with a state-of-the-art lab and launch of Non-invasive Pre-Natal Testing (NIPT), alongside a phased expansion of its test menu to deepen clinical offerings in precision diagnostics.

For FY26, consolidated revenue grew 21% YoY to ₹829.04 crore. In the Pathology business, franchise revenue increased 18% YoY, while partnership revenue, grew 32% YoY. Test volumes reached 209.6 million for the year, marking a 23% YoY growth. Consolidated EBITDA rose 38% YoY to ₹262.04 crore, and Profit After Tax grew 81% YoY to ₹162.85 crore, underscoring sustained growth momentum and operating leverage

Senior management remarks:

“Thyrocare reported a strong performance this quarter, driven by continued focus on operational efficiency, network expansion, and value-driven diagnostics. During the period, we also strengthened our specialty portfolio with the addition of allergy testing and entry into genomics through the launch of NIPT, with a phased expansion of the test menu underway. Thyrocare continues to expand its reach in underserved regions and scale its franchise and partner network, while remaining committed to delivering high-quality, affordable healthcare services across India”

– Rahul Guha, MD & CEO, Thyrocare Technologies Ltd.